本文源自：金融界AI电报 辉瑞(PFE.N)预计2026年营收为595亿美元至625亿美元。 ...

格隆汇12月16日｜辉瑞(PFE.US)：预计2026年营收为595亿美元至625亿美元。预计2026年调整后EPS为 2.80美元至3.00美元。预计2025年营收约为620亿美元，此前预计为610亿至640亿美元。预计2026年经调 整研发费用为105亿至115亿美元。 ...

Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading. ...

(2)(2)(2) NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance while revising its November 4, 2025 full-year 2025 Revenue guidance and reaffirming all other components of full- year 2025 financial guidance. The accompanying presentation can be found at www.pfizer.com/investors. (2)FULL-YEAR 2026 REVENUE GUIDANCE (2)(2)(2)(3) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance is revised to appr ...

天眼查数据显示，Pfizer Inc.成立日期1989年10月07日，法定代表人孟昱，所属行业为化学药品制剂制 造，企业类型为有限责任公司(外国法人独资)，企业规模为中型，参保人数935，注册资本8040万美 元，实缴资本8040万美元，注册地址为辽宁省大连经济技术开发区大庆路22号。股东信息如下： 国家药品监督管理局药品审评中心数据显示，2025年12月16日，Pfizer Inc.的PF-07275315注射液申请已 获受理，受理号为JXSL2500239。 受理号JXSL2500239药品名称PF-07275315注射液药品类型治疗用生物制品申请类型进口注册分类1企业 名称Pfizer Inc.;PFIZER (CHINA) RESEARCH & DEVELOPMENT CO., LTD.;承办日期2025年12月16日 来源：新浪财经-鹰眼工作室 股东名称持股比例认缴出资额认缴出资日期首次持股日期美国晖致企业公司100%8040万美元2017年11 月30日2023年06月09日 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、 ...

Market Performance - On Monday, major U.S. stock indices collectively declined, with the Dow Jones down 0.09% at 48,416.56 points, the Nasdaq down 0.59% at 23,057.41 points, and the S&P 500 down 0.16% at 6,816.51 points [1][2]. Tesla Highlights - Tesla's stock rose over 3%, reaching a nearly one-year high, with a market value increase of over $53 billion in one night [1][4]. - CEO Elon Musk's net worth surpassed $600 billion, making him the first person in history to achieve this milestone [4]. iRobot Situation - iRobot's stock plummeted over 72% after the company filed for bankruptcy protection, planning to be taken over by its main Chinese supplier and manufacturer, leading to its delisting [1][5]. Chinese Stocks Performance - The Nasdaq Golden Dragon China Index fell by 2.17%, with notable declines in stocks such as Baidu (down nearly 5%) and Alibaba (down over 3%) [1][7]. Nasdaq Trading Mechanism - Nasdaq plans to submit a proposal to the SEC to introduce a near-around-the-clock trading mechanism, extending trading hours from 16 to 23 hours per week [1][14]. - The new trading schedule would include two trading periods: a daytime session starting at 4 AM and ending at 8 PM, and a night session from 9 PM to 4 AM [14][15].

Group 1 - Broadcom shares fell over 5%, while Apple and Amazon rose over 1%, and Tesla increased by over 3%, adding $53.7 billion (approximately 378.6 billion RMB) to its market value [1] - Elon Musk's net worth reached $677 billion, making him the first person in history to surpass the $600 billion mark, previously no one had crossed $500 billion [3] - iRobot officially declared bankruptcy with a stock value of zero after finalizing its restructuring plan on December 15, resulting in a 72.69% drop in its shares [3] Group 2 - The Nasdaq Golden Dragon China Index fell by 2.17%, with major Chinese stocks declining; Baidu dropped nearly 5%, and Alibaba, Xpeng Motors, and others fell over 3% [5] - WTI crude oil futures decreased by 1.08% to $56.82 per barrel, while Brent crude oil futures fell by 0.92% to $60.56 per barrel [6] - Bitcoin fell below $86,000 for the first time in two weeks, dropping 3.3% to $85,578, approximately 30% down from its record high of over $126,000 [6][7] Group 3 - Over the past 24 hours, more than 190,000 traders were liquidated, resulting in a total loss of $670 million (approximately 4.7 billion RMB) [9] - The New York Federal Reserve's manufacturing index unexpectedly shrank to -3.9 in December, indicating a contraction in economic activity, significantly below the expected median of 10 [11][13] - Federal Reserve Governor Milan suggested that the current monetary policy is too tight and advocated for a faster pace of rate cuts, citing signs of a cooling labor market [13]

在经历三次自研GLP-1药物折戟的挫折后，全球制药巨头辉瑞（Pfizer）以一场"豪购"宣告其重返千亿美 元减肥药战场的决心。 12月9日，辉瑞与复星医药旗下核心子公司——药友制药正式签署协议，以高达20.85亿美元的总交易 额，获得后者自主研发的口服小分子GLP-1受体激动剂YP05002项目的全球独家权利。这笔交易创下中 国创新药出海早期阶段交易金额的纪录。 根据协议，药友制药将获得1.5亿美元首付款，并有资格获得最高19.35亿美元的里程碑付款及未来的销 售分成。值得注意的是，YP05002目前仅处于澳大利亚I期临床阶段，尚无后期数据支撑。辉瑞为此押 下重注，直接反映了其在明星靶点GLP-1赛道上的深层焦虑与紧迫感——面对诺和诺德、礼来两大巨头 的绝对领先，以及自身核心产品专利悬崖的逼近，辉瑞已别无选择，必须通过资本手段快速卡位。 此举是辉瑞在一个月内第二次重金布局代谢疾病领域。此前，其刚以约100亿美元收购Metsera。接连大 手笔投资，凸显了辉瑞将减肥药确立为未来增长核心的坚定战略。 同时，这笔交易也将中国创新药企的研发价值推至新的高度，中国创新药的出海，正从产品授权迈向更 深层次的全球价值兑现新 ...

在经历三次自研GLP-1药物折戟的挫折后，全球制药巨头辉瑞（Pfizer）以一场"豪购"宣告其重返千亿美元减肥药战场的决心。 12月9日，辉瑞与复星医药（600196）旗下核心子公司——药友制药正式签署协议，以高达20.85亿美元的总交易额，获得后者自主研发的口服小分子GLP-1 受体激动剂YP05002项目的全球独家权利。这笔交易创下中国创新药出海早期阶段交易金额的纪录。 根据协议，药友制药将获得1.5亿美元首付款，并有资格获得最高19.35亿美元的里程碑付款及未来的销售分成。值得注意的是，YP05002目前仅处于澳大利 亚I期临床阶段，尚无后期数据支撑。辉瑞为此押下重注，直接反映了其在明星靶点GLP-1赛道上的深层焦虑与紧迫感——面对诺和诺德、礼来两大巨头的 绝对领先，以及自身核心产品专利悬崖的逼近，辉瑞已别无选择，必须通过资本手段快速卡位。 此举是辉瑞在一个月内第二次重金布局代谢疾病领域。此前，其刚以约100亿美元收购Metsera。接连大手笔投资，凸显了辉瑞将减肥药确立为未来增长核心 的坚定战略。 同时，这笔交易也将中国创新药企的研发价值推至新的高度，中国创新药的出海，正从产品授权迈向更深层次的全球价 ...

Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases. ...